Engines will not be re-sealable, and will come with an HPD-spec clutch, engine mount, chain guard and hardware. The GXH50 Kid Kart engine will come factory-sealed from HPD to eliminate "blueprinting" of the engine. To join the Honda Racing Line, a racer must simply provide proof of current membership in a nationally-recognized sanctioning body; provide official race results from at least two events in the past year; complete and submit the registration form; and be a resident of the U. With the new engine package, HPD seeks to assist sanctioning bodies and participants in rebuilding the category, lowering operating costs while bringing traditional Honda reliability and quality to Kid Karting. Launched in 2009, the Honda Racing Line is a program targeted at licensed participants in sanctioned amateur and entry-level professional racing. Founded in 1993, Honda Performance Development (HPD) is the technical operations center for high-performance Honda racing cars and engines, and operates at race circuits around the world from its headquarters in Santa Clarita, California. Following requests from the marketplace, HPD offers the Honda GXH50, and subsequent HPD installation kit, as a replacement engine for the Kid Kart class. The Honda GXH50, available to racers, retail shops and series through the Honda Racing Line, is an effort by HPD to address issues that have negatively affected the growth of Kid Karting in recent years, and help the entry-level category return to popularity. "Kid Karting is one of the earliest forms of motorsport available to youth with an interest in racing," said Marc Sours, senior manager of HPD’s Commercial Division.Honda Performance Development, the racing arm of American Honda Motor Co. or Canada.S. Retail price of a complete GXH50 will be $829, and both race shop and series inquiries are welcome. Engine life is expected to be well in excess of 200 hours, and the HPD GXH50 is intended to provide both lower maintenance costs and better engine parity than other currently available engines. Through the Honda Racing Line, karters and other racers can arrange direct, door-to-door delivery of parts and complete engines." Originally intended as a way for families and their children – typically between five and seven years old – to gain an introduction to karting, the Kid Kart class in recent seasons has been negatively impacted by high engine costs and a lack of control over the current engine platform. Through our Kid Kart engine program, we hope to make it easier for these young racers and their families to discover the fun of our sport. . HPD offers a line of race engines for track applications from prototype sports cars to karting; and showcases "fun" products for professional, amateur and entry-level efforts. The Honda Racing Line was formed to provide its members with a direct connection to Honda Performance Development and its unparalleled record of success at the highest levels of motorsport. "One of the DC Motors 48V Manufacturers in China https://www.lbdcmotor.com/product/dc-motor-48v/ goals of the Honda Racing Line is to support these novice racers., is expanding its range of karting products with the introduction of a new Kid Kart engine designed to improve quality, reliability and balanced performance at a low cost to the competitor. HPD’s support will include a rules package designed to maintain the integrity of the program.

Just last month, Iraqi Prime Minister al-Abadi discovered that 50,000 “ghost soldiers” were listed on the government payroll, costing Iraqis approximately $380 million a year. Specifically about two issues that we confront both domestically and internationally – corruption and violent extremism.S and European values as we continue to work together to build a more prosperous and democratic world and a more stable and peaceful path to the future. And we have made progress on that front. Embassy. And this same level of cooperation will be required to overcome the phenomenon of violent extremism — the ideology, the networks, the capacity to recruit young people, and the lack of economic opportunity, quality education, respect for human rights, and good governance that enable it to spread. Where there is weak governance or a lack of quality education, economic opportunity, or respect for human rights, citizens are most at risk to being alienated by or from their governments and each other. This requires much more than simply increasing online efforts to keep pace with the saturation of terrorist recruitment and other messaging on the Internet. Undergirding fair, accountable, and clean governance in our trade relations is a good place to start.It might be streamlining the process of getting a license, so there are fewer discretionary transactions to be tampered with in the first place. provides $600 million dollars in assistance each year to help ensure foreign governments have the capacity to implement those commitments, including our support regional capacity building initiatives in Prague, Budapest, Vienna, and Paris.The U.Significantly strengthening the preventative dimension of our policy offers many advantages. We can applying the preventive lens to both anti-corruption efforts and to more effectively address the underlying grievances and conflicts that China Electric Motors Factory https://www.lbdcmotor.com/ feed violent extremism.But the cornerstone of prevention remains boosting transparency – helping everyday people understand what the actual rules are so that they can push back if they are asked to pay “extra” to get a driver’s license. At every level, from negotiating on Iran’s nuclear program to guaranteeing safe cars for drivers and medicine for patients, the EU has become an unparalleled force for good on the world stage and in the lives of its citizens.First, corruption’s impact on democracy: When politicians steal public funds rather than spend them appropriately, schools go without books, patients go without medicine, and merchants go without bridges and roads. It also requires amplifying the voices of Muslim educators, leaders, and others who promote tolerance and peace, welcome diversity, and who are more influential than any government in discrediting and speaking out against the hijacking of religion in the name of violence against civilians.Corruption has a similarly pernicious effect on economic growth, competition, and innovation. And the U. That frays the fabric of the social contract, alienating the people and undermining attempts by government to assert legitimacy or establish democracy. As Secretary Kerry made clear in his visit to Paris last week, we stand with the citizens of Paris and beyond not just in horror and outrage for this vicious act of violence, which we see far too often around the globe, but in commitment both to the cause of confronting extremism and in the cause which the extremists fear so much and which has always united the U.Across Central and Eastern Europe and the Balkans, our embassies are stepping up their work with governments, civil society, the media, and business communities to promote accountability. But we can identify the most vulnerable—for example, working with Somali communities in Kenya or with border communities between Niger and Nigeria. In Georgia, the government is following through on its OGP commitments to combat corruption by making political party financing transparent, and developing an online system for government procurement. It will help focus more attention on the longer-term, civilian aspects of the violent extremist challenge we face that have yet to receive the policy support or resources they deserve. The effects and influence of corruption are so dangerous to economic prosperity that the World Bank has labeled corruption as “public enemy number one. Young people are often most prone to radicalize. When companies have to pay bribes to cut through red tape, it actually incentivizes the creation of more red tape, slowing transaction times and raising business expenses.As we work to both prevent and combat corruption, we have to constantly remind ourselves why we care so much about this threat. Citizens feel betrayed by these scams, indirectly because their taxes and resources are enriching nominal “public servants,” but also directly because they do not receive the security and protection that they both finance and require.Websites like I_Paid_A_Bribe. In Nepal, a wiki platform supported by the NGO The Accountability Lab crowd-sources information on topics like how to get a birth certificate or driver’s license.So today in talking to you about how we ensure civilian security, I would start by noting that we face a common challenge in insecurity and fragility.But only focusing on corruption once it has occurred is only half the battle. The United States is committed to combating and countering terrorism while respecting human rights; continuing our intelligence cooperation, strengthening aviation security and showing our publics—both in the United States and Europe—that privacy and security need not be mutually exclusive.. This community—which rose from the ashes of devastation wrought by World War II – has become a beacon of international cooperation and one of the foundations for lasting peace in Europe.

Understand that you don’t have to be compliance expert to be compliant -- as your telematics partner, inthinc will continue to be an expert resource on federal rules and regulations providing updates and insights into how these rules affect your fleet. Fleet managers can rely on our compliance professionals to direct them in the specifics of the ruling and provide ’best practices’ for implementing a solution. It also suggests the rule will "save 26 lives and 562 injuries" a year, according to a recent press release."The ELD mandate focuses on reducing the burdensome task of manual paperwork associated with hours-of-service (HOS) record keeping.inthinc Provides Direction and Leadership for Fleets Required to Meet ELD Mandate -- SALT LAKE CITY, UT--(Marketwired - December 11, 2015) - inthinc Technology Solutions Inc.Fleets currently outfitted with the inthinc solution are already ahead of the ELD curve. According to the mandate, those fleets will have four years to fully implement an ELD solution meeting the mandate requirements, while companies that have yet to install a device will be held to the December 2017 deadline."Companies struggle with compliance on several levels. The implementation of eLogs will ultimately lead to a reduction in HOS violations, making for safer, more efficient, and federally compliant fleets. Additionally, inthinc has developed proprietary applications improving in-vehicle driver performance and safety in real time., a leading telematics solution provider, today announced a pathway to compliance in regards to the announcement of the final ruling and passage of the ELD mandate from the Federal Motor Carrier Safety Administration (FMCSA) -- slated to be published in the Federal Register next week.About inthincinthinc is a leading global provider of mobile workforce solutions for businesses of all sizes delivered as Software-and-Hardware-as-a-Service (SHaaS). It is our goal to help mitigate and/or eliminate the struggles and burdens experienced on a daily basis by our customers," said Todd Follmer, CEO, inthinc.Rest assured -- inthinc is a solution based on safety, efficiency, and compliance. The inthinc solution enables businesses to meet the challenges associated with managing private fleets, and improve the productivity of their mobile workforce by extracting actionable business intelligence from real-time and historical vehicle and driver behavioral data.A Pathway to ComplianceThere are several items to consider regarding the ELD rule, including:Ensure the technology you are using is providing a path forward for future regulations such as Driver/Vehicle Inspection Reports (DVIR), etc.Prepare your drivers and organization ahead of time -- offer training and education for a successful implementation. "Providing a solution that promotes safety and creates efficiencies within the organization China Electric Motors Suppliers https://www.lbdcmotor.com/ while on the road to compliance is one of our primary objectives. Furthermore, it looks to improve the overall accuracy and quality of logbooks via electronic logs (eLogs). We will continue to innovate and develop technology in compliance with federally mandated regulations, including ELD-based rules."Safety is at the very core of our telematics solution," explains Oliver Neil, EVP of Product Strategy, inthinc. "inthinc has the technology and infrastructure to meet the requirements of the ELD mandate -- a regulation that will ultimately save lives and make fleets of all sizes more efficient. The FMCSA says the rule will save the industry $1 billion a year, mostly in time and money saved on paperwork."As a leader in the telematics industry, inthinc continuously monitors federally regulated developments closely, and will continue to provide the necessary guidance and information to its current customers as well as to fleets of any size requiring the deployment of an ELD solution.

Amendment yesterday to our collaboration with AstraZeneca under which Chi-Med has agreed to provide up to $50 million for the joint-development costs of savolitinib in return for a 5 percentage point increase in the tiered royalty rates payable on savolitinib sales across all indications in all markets outside of China.m. investors will also be held today at 9:00 a.8m) due primarily to continued expansion of coronary artery disease prescription drug business.S.6m); Total sales of non-consolidated joint ventures up 9% to $249.9 million net proceeds of our March 2016 Nasdaq listing. She Xiang Bao Xin ("SXBX") pill - our most important commercial product, is a prescription vasodilator proprietary to our joint venture: Accounted for approximately 12% of China’s over $1.ukCitigate Dewe (Mobile)RogersonU.8m) at the Chi-Med Group level, including cash and cash equivalents, short-term investments and unutilized banking facilities. 3.Innovation Platform - Seven drug candidates in 25 clinical trials (H1 2015: 17) including four pivotal Phase III studies (H1 2015: 1).5 million (H1 2015: $15. Glioblastoma: Planning underway to start a Phase II study in glioblastoma, a primary brain cancer with EGFR gene amplification, in early 2017. A conference call for U. Our partnerships with major global pharmaceutical companies, created when the global scope of our drug candidates began to emerge, continue to allow us to broaden development plans and represent important global marketing and distribution resources. Substantially completed move to new factory in Shanghai, almost tripling the manufacturing capacity of our Prescription Drugs joint venture. NSCLC with brain metastasis: Phase Ib study in NSCLC patients with brain metastasis ongoing; granted China FDA Phase II/III clinical trial application clearance granted in July 2016; target to initiate pivotal registration study in H1 2017. Completed enrollment of a Phase II study of sulfatinib in 81 broad-spectrum NET patients in China; median Progression Free Survival ("PFS") not yet reached; now enrolling two Phase III studies, named SANET-p (in pancreatic NET patients) and SANET-ep (in extra-pancreatic NET patients), with primary endpoint median PFS; Phase III top-line data expected in 2018.Our pragmatic approach to finance and risk management has enabled us to build our drug pipeline over a dozen years. Subject to approval in the PRCC indication, Chi-Med will receive a 5 percentage point increase in the global (excluding China) tiered royalty rate payable on savolitinib sales across all indications, thereby increasing the tiered royalty to 14% to 18%.8m). We target to initiate pivotal registration trials on two further drug candidates before the end of H1 2017, including:Savolitinib Phase III in c-Met-driven PRCC patients; Epitinib Phase II/III in first-line patients with EGFR-mutant NSCLC patients with brain metastasis; and Savolitinib Phase III in combination with Tagrisso® in second-line NSCLC (T790M-/c-Met+) patients. Non-small cell lung cancer ("NSCLC"): a.Conference Call and Webcast Information:An analyst presentation and webcast will be held today at 9:00 a.6 million (H1 2015: $10.dible@citigatedr.1 million (H1 2015: $19.The progress of our drug pipeline and strong cash position, resulting from our increased commercial profits and recent Nasdaq listing, have enabled us to renegotiate our collaboration agreement with AstraZeneca to take a greater share in the potential long-term economic value of savolitinib in return for increasing our investment in savolitinib’s development. HKT) at Citigate Dewe Rogerson, Third Floor, 3 London Wall Buildings, London, EC2M 5SY.comTrout Group (Mobile)David Dible, +44 7967 566 919 david.5m).7 million (H1 2015: net income $2.S. Immunology: Australia Phase I study completed with no evidence of the hypertension/gastrointestinal toxicities encountered by the first-generation Syk inhibitor (fostamatinib); U. 2.m. Initiated or continued four further Phase Ib/II studies in first-, second- and third-line NSCLC patients, including (i) as a monotherapy in NSCLC patients with c-Met mutations that result in Exon 14 skipping; (ii) as a monotherapy in pulmonary sarcomatoid carcinoma ("PSC") patients with mutations that result in Exon 14 skipping; (iii) as a combination therapy with Iressa® (gefitinib) in NSCLC patients with EGFR mutations and who have failed first-line EGFR TKI therapy; and (iv) as a combination therapy with Tagrisso® in third-line NSCLC patients who have failed Tagrisso® therapy.3 million (H1 2015: $26.3 million (H1 2015: $55. UK Analysts Meeting and Webcast Scheduled Today at 9:00 a. dollar terms.b. Available cash resources of $197.S. specialist investors and strengthened our cash position. All other provisions of the 2011 Agreement will remain unchanged. A Phase Ib dose finding study of savolitinib in combination with Taxol® (docetaxel) in gastric cancer patients with c-Met over-expression is ongoing in South Korea.S.5%. Food & Drug Administration ("FDA") and European Medicines Agency ("EMA"); alignment on plans for global savolitinib monotherapy Phase III study in c-Met-driven papillary renal cell carcinoma ("PRCC") patients. NET (first-line): a.Group ResultsConsolidated revenue up 27% to $104.S.Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited ("CK Hutchison") (SEHK: 0001). and European regulatory authorities in end-of-Phase II meetings on savolitinib and completing enrollment of our first Phase III study on fruquintinib. Commercial Platform - a deeply established, cash-generative, pharmaceutical business in China - a commercialization framework for our Innovation Platform candidate drugs.Completed Nasdaq listing, raising net proceeds of $95.0 million (H1 2015: $24. This triggered a $10 million milestone from AstraZeneca to Chi-Med in June 2016. Biliary tract cancer: Planning underway to start a Phase II study in China in late 2016. Under the amendment, Chi-Med will contribute up to $50 million, spread primarily over three years, to the joint-development costs of the global pivotal Phase III study in c-Met-driven PRCC. Total consolidated sales up 48% to $82.co.9m); SXBX pill represents 87% of the sales of SHPL, our joint venture, which contributed 91% of our $16.S. Production facility in Suzhou, China, operational and ready to support fruquintinib’s potential commercial launch. Proof-of-concept studies of savolitinib as a monotherapy in gastric cancer patients with c-Met gene amplification are ongoing in South Korea and China; promising response data, was published by Dr.3.S. Triggering about $114 million total cash compensation and subsidies for the surrender of its land-use rights for its old factory site. Phase I dose confirmation study in Caucasian patients - currently in 200mg cohort and closing in on China 300mg Phase III dose; expected to complete in H2 2016. Planning to publish proof-of-concept or pivotal trial data on four drug candidates at scientific meetings through Q1 2017. GAAP") and in U. We also conduct our business through three non-consolidated joint ventures, which are accounted for under the equity accounting method as non-consolidated entities in our consolidated financial statements.9m). Within this announcement, we refer to certain financial results reported by such non-consolidated joint ventures, which are based on figures reported in their respective consolidated financial statements prepared pursuant to International Financial Reporting Standards (as issued by the International Accounting Standards Board).m. Unless otherwise indicated, references to "subsidiaries" refer to our consolidated subsidiaries and joint ventures (excluding non-consolidated joint ventures). Total sales of non-consolidated joint ventures up 9% to $249. Epitinib: Highly differentiated inhibitor of the EGFR designed for optimal blood-brain barrier penetration: 1. dollar currency unless otherwise stated. immunology IND application submitted in H1 2016 - U. generally accepted accounting principles 2016 is the first full year of Seroquel® commercialization under Chi-Med.7 million (H1 2015: $125.6 million (H1 2015: $10. We believe this benefits both Chi-Med and AstraZeneca as it allows us to accelerate and broaden savolitinib’s late-stage development in multiple oncology indications.All aspects of our Innovation Platform’s risk-balanced, innovative drug pipeline have moved forward, including progress in aligning with U.co.9m) spending mainly for 25 clinical trials, four of which are pivotal Phase III studies on fruquintinib and sulfatinib, as well as the continued expansion of our scientific team, which now includes over 310 scientists and staff. Consequently, we view the future with great confidence. Seroquel® - prescription antipsychotic under exclusive commercial license from AstraZeneca within China: Accounted for approximately 5% of China’s antipsychotic prescription drug and 46% of the generic quetiapine market; Seroquel® is the only extended release ("XR") quetiapine formulation approved in China; H1 2016 sales up 282% to $17.4. In the first half, we completed our Nasdaq listing, which broadened our exposure to U. -- HONG KONG, CHINA -- (Marketwired) -- 08/02/16 -- Hutchison China Meditech Limited (NASDAQ: HCM)Nasdaq: HCMHutchison China MediTech Limited ("Chi-Med") Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical ProgramsGroup revenue up 27% to $104.1 million (H1 2015: $94. Commercial Platform: Continued strong growth in cash flow and profit - representing a solid and stable financial base that underpins a significant portion of Chi-Med’s current market value.S.Simon To, Chairman of Chi-Med, said: "Chi-Med has once again made very considerable progress at both the operating and strategic levels.3 million (H1 2015: $12.2. Thyroid cancer: Initiated Phase II proof-of-concept study in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer or medullary thyroid cancer in China.6 million (H1 2015: $229. FDA feedback received, now preparing to submit additional data; planning global rheumatoid arthritis Phase II study for 2017. 5.S. POST PERIOD EVENT: Amendment of Co-Development Agreement with AstraZeneca on Savolitinib global development plan:In order to accelerate savolitinib’s global development, as announced yesterday, Chi-Med and AstraZeneca agreed to amend the 2011 global licensing, co-development and commercialization agreement regarding savolitinib.1m) consolidated Prescription Drugs operating profit in H1 2016. Sales in our OTC drug joint venture were down marginally due to tight manufacturing capacity resulting from the move to new factory in Bozhou, Anhui province; despite this, our OTC drug joint venture’s portfolio of mature, market leading products, contributed 99% of our $8. BST (4:00 p.b. Consumer Health business stable despite over-the-counter ("OTC") drug capacity constraints - consolidated sales up 44% to $14. Expect to receive about $70 million second installment of the total approximately $114 million land compensation and subsidies from the Shanghai government, leading to an estimated one-time gain to the Chi-Med Group of over $35 million in Q4 2016.9m) and net loss attributable to Chi-Med of $13.5 million (H1 2015: $82.9m), reflecting a sharp increase in clinical investment.8 million (H1 2015: $103. EDT. For all dial-in numbers please use conference ID "Chi-Med".5% to 14.3 million (H1 2015: $55. Total net income attributable to Chi-Med from our Commercial Platform up 12% to $22.4m); and total sales of non-consolidated Prescription Drugs joint venture up 22% to $126. Commercial Platform - Total consolidated sales up 48% to $82.1m); and total sales of non-consolidated Consumer Health joint venture down 2% to $122. EDTLondon: Tuesday, August 2, 2016: Chi-Med (AIM/NASDAQ: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global market, today announces its unaudited financial results for the six months ended June 30, 2016. Based MediaEnquiriesBrad Miles, BMC +1 (917) 570 7340 bmiles@bmccommunications.6 million (H1 2015: $45.5 million at Group level as of June 30, 2016, which includes cash and cash equivalents, short-term investments and unutilized bank facilities. Jeeyun Lee of Samsung Medical Center in April 2016 at the American Association of Cancer Research meeting. Theliatinib: EGFR inhibitor, over five times more potent than Tarceva® (erlotinib), with potential in patients with solid tumors presenting EGFR gene amplification: Esophageal cancer/Head and Neck: Phase I dose escalation study ongoing in China; target to start Phase Ib proof-of-concept studies by the end of 2016. Hematological cancer: Granted China DC Motors 48V Suppliers https://www.lbdcmotor.com/product/dc-motor-48v/ China FDA Phase I to Phase III clinical trial application clearance in H1 2016 - target to start China Phase I dose escalation in patients with hematologic malignancies in H2 2016; Australia Phase I dose escalation currently in second dose cohort (200mg) and expected to complete in H1 2017; U and net income attributable to Chi-Med of $0.carlisle@cdrconsultancy.S. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Strengthened cash position: Available cash resources of $197.m. Initiated global Phase Ib dose finding study of savolitinib in combination with anti-programmed death-1 receptor ligand ("PD-L1") antibody, durvalumab, in clear cell renal cell carcinoma ("ccRCC") patients.1m) consolidated Consumer Health operating profit in H1 2016. 2. Significant property-related payment expected to come in H2 2016. Gastric Cancer: a.5 billion botanical coronary artery disease prescription drug market, full patent protection through 2029; H1 2016 sales up 16% to $110. Colorectal cancer (third-line or above): Completed enrollment of a Phase III study, named FRESCO, to test fruquintinib as a monotherapy among third-line metastatic colorectal cancer patients in China; top-line Phase III data expected to be reported in early 2017; plan to submit the China NDA, subject to positive FRESCO outcome, by mid-2017;2.Consolidated revenue of $22. NSCLC (third-line): Began enrolling a Phase III study, named FALUCA, to test fruquintinib in third-line NSCLC patients in China, in late 2015 - now over 30 clinical centers are operational; expect to complete enrollment in H1 2017; top-line Phase III data expected to be reported in late 2017; plan to submit China NDA, subject to positive FALUCA outcome, during H1 2018.1 million (H1 2015: $19.Post-period Event: Amendment of collaboration with AstraZeneca AB (publ) ("AstraZeneca") - Chi-Med investing $50 million, mainly over three years, to accelerate savolitinib global development in return for 5% point increase in tiered royalty range.EnquiriesInvestor EnquiriesChristian Hogg, CEO +852 2121 8200International MediaEnquiriesAnthony Carlisle, +44 7973 611 888 anthony. NSCLC (first-line): Planning underway to start Phase Ib dose finding study of fruquintinib in combination with Iressa® in first-line EGFR-mutant NSCLC patients in China in late 2016.S.b. Gastric cancer (second-line): Completed dose finding stage of fruquintinib Phase Ib study in combination with Taxotere® (paclitaxel). We now have multiple shots at success with four pivotal studies underway today, and three more likely to initiate by H1 2017, on a diversified group of drug candidates.5 million (H1 2015: $82.ukCitigate Dewe (Mobile)RogersonPanmure Gordon (UK)LimitedRichard Gray / +44 (20) 7886 2500Andrew PottsAbout Chi-MedChi-Med is an innovative China-based biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.Prescription Drugs business performing very well - consolidated sales up 49% to $67.S. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China. We have also made great progress in the clinic on sulfatinib, epitinib, HMPL-523, HMPL-689 and theliatinib, all of which are also potential global first-in-class or best-in-class drug candidates. Potential global first-in-class spleen tyrosine kinase ("Syk") inhibitor - major potential in immunology and oncology: 1.HMPL-689: Potential global best-in-class, highly selective phosphoinositide 3-kinase delta ("PI3Kδ") inhibitor, which is over five times more potent than Zydelig® (idelalisib):Hematological cancer: Initiated Phase I study in healthy volunteers in Australia in H1 2016, now in fifth cohort and expected to complete Phase I dose escalation in H2 2016; plan to start Phase I dose escalation in patients with hematologic malignancies in Australia in H1 2017.8m).6m) mainly resulting from solid progress on Seroquel®.Savolitinib: Potential global first-in-class mesenchymal epithelial transition factor ("c-Met") inhibitor currently in 12 main clinical studies worldwide in multiple tumor types including kidney, lung and gastric cancers as a monotherapy and in combination with other targeted and immunotherapy agents:1.9 million. Initiated global Phase IIb study of savolitinib in combination with Tagrisso® (osimertinib) in second-line NSCLC patients with epidermal growth factor receptor ("EGFR") mutations who have failed first-line EGFR tyrosine kinase inhibitor ("TKI") therapy and harbor c-Met gene amplification. Continue to enroll patients in Phase Ib expansion stage.2 million (H1 2015: $4.8m); Total net income attributable to Chi-Med from our Commercial Platform up 12% to $22. Completed end-of-Phase II meetings with U. EXPECTED MAJOR NEAR-TERM CATALYSTS: We target to publish data on four drug candidates in five Phase Ib-III studies before the end of Q1 2017, including:Savolitinib Phase II data in PRCC patients; Epitinib Phase Ib data in NSCLC patients with brain metastasis; Fruquintinib Phase II data in third-line NSCLC patients; Sulfatinib Phase II data in pancreatic and extra-pancreatic NET patients; and Fruquintinib Phase III top-line data in third-line or above colorectal cancer patients. Net income attributable to Chi-Med of $0.3. After total aggregate sales of savolitinib have reached $5 billion, the royalty will step down over a two year period, to an ongoing royalty rate of 10. Initiated U. Solid performance despite the weakening of the Chinese renminbi ("RMB") over the last year which reduced both our top- and bottom-line growth rates, during the first half of 2016, by -6% in U.S.Once again, our Commercial Platform has generated increased cash flows helping fund our Innovation Platform activities as well as providing a first-class marketing and distribution channel in China for our drug candidates, if they are approved.S. BST U. Each is expected to read-out over the next three years. The results of these pivotal studies will emerge during 2017-2019, and we believe that if they prove successful, substantial benefits can be created for patients and shareholders alike.